Welcome to our dedicated page for Zura Bio SEC filings (Ticker: ZURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zura Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zura Bio's regulatory disclosures and financial reporting.
Zura Bio Limited reported that its Board adopted an Executive Severance Benefit Plan covering certain employees, including current named executive officers. Under the plan, if an eligible executive is terminated without cause or resigns for good reason after at least 91 days of employment, the Chief Executive Officer may receive a lump sum equal to 12 months of base salary, while other named executive officers and certain executives may receive nine months of base salary.
If a qualifying termination occurs within 12 months after a change in control, the benefits increase. In that case, the Chief Executive Officer may receive 18 months of base salary, 150% of target annual bonus, a prorated bonus for the year of termination based on actual performance, and up to 18 months of COBRA or comparable health coverage reimbursement. Other named executive officers and certain executives may receive 12 months of base salary, 100% of target annual bonus, a prorated actual-performance bonus, and up to 12 months of COBRA or comparable coverage reimbursement.
Zura Bio Limited reported that it has prepared an updated corporate presentation as of September 4, 2025. The presentation may be used at conferences and investor meetings to explain the company’s business and outlook.
The updated deck is filed as Exhibit 99.1 and is also available in the News & Events section of Zura Bio’s investor website. The company notes that this material is being furnished under a disclosure item for investor information and is not considered filed for liability purposes under U.S. securities laws or automatically incorporated into other SEC filings.
Zura Bio Limited filed a current report to furnish a press release dated August 20, 2025. The company states that the information in Item 7.01 and Exhibit 99.1 is being provided under Regulation FD and is considered “furnished,” not “filed,” which means it is not subject to certain liability provisions of the Exchange Act unless later specifically incorporated by reference. The filing identifies the press release as Exhibit 99.1 and also includes a cover page interactive data file as Exhibit 104.
Zura Bio Limited ownership disclosure: A group led by Venrock entities and two individuals reports beneficial ownership of 6,353,353 Class A Ordinary Shares, representing 9.99% of the class as of June 30, 2025. The position reflects direct Class A shares and pre-funded warrants exercisable into additional Class A shares, but those warrants include a Beneficial Ownership Blocker that prevents exercise that would push the group above the 9.99% threshold. The percentage is calculated using 61,874,998 outstanding Class A shares plus 1,722,137 shares issuable on warrant exercise. Voting and dispositive power are shown as shared for the 6,353,353 shares, with no sole voting or dispositive power reported.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report a collective stake of 4,616,514 Class A Ordinary Shares in ZURA Bio Ltd, representing 7.13% of the class. The filing shows the reporting persons hold shared voting and shared dispositive power for all 4,616,514 shares and no sole voting or dispositive power. The ownership calculation uses a share base of 64,763,950, which combines 61,874,998 outstanding ordinary shares and 2,882,952 pre-funded warrants that the reporting persons could convert subject to a 9.99% maximum exercise limitation. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Zura Bio Limited reported advancing clinical programs while continuing to operate at a loss. As of June 30, 2025 the company held $154.5 million in cash and cash equivalents and reported a net loss of $15.993 million for the three months ended June 30, 2025 and $33.435 million for the six months ended June 30, 2025, leaving an accumulated deficit of $189.3 million. The balance sheet shows total assets of $157.8 million and total shareholders' equity of $127.4 million.
The company is a clinical-stage immunology company developing tibulizumab (ZB-106), which entered a global Phase 2 study TibuSHIELD in May 2025 (~180 adults) and previously initiated TibuSURE (Dec 2024, ~80 participants). Zura also lists two other clinical assets, crebankitug and torudokimab. The filing discloses contingent milestone and royalty obligations under multiple license agreements and a pending $5.0 million invoice related to a finder’s fee that the company is reviewing. Management states it expects existing liquidity to fund operations for the next twelve months.
Zura Bio Limited furnished a press release announcing its second quarter 2025 financial results and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states the results disclosure is furnished under Item 2.02 rather than "filed," and the press release itself is incorporated by reference into the exhibit list.
The company also confirms its securities trading symbol and that it qualifies as an emerging growth company. No financial tables, specific revenue, earnings or other numeric results are included within the 8-K text; interested readers must refer to Exhibit 99.1 for the full press release content.
Zura Bio Limited (Nasdaq: ZURA) filed an 8-K announcing a leadership transition in its finance organization. The Board has appointed Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. Hyllengren brings more than two decades of biotech experience, most recently serving as CFO/COO of Atara Biotherapeutics and holding multiple senior finance roles at Amgen. His compensation package includes a $475,000 base salary, a target bonus equal to 40 % of salary, and an inducement option for 672,000 Class A shares that vests over four years.
Current CFO Verender Badial tendered his resignation on June 25, 2025. He will stay through the effective date and remain as a non-executive employee until July 31, 2025 to ensure continuity. A Settlement Agreement provides Badial with cash severance and benefits totaling roughly £295,000, accelerated vesting on options covering 186,561 shares, transfer restrictions on those shares for up to three years, and an extension of option exercise periods. Options for 303,100 shares granted on May 8, 2025 will be forfeited.
Key implications for investors:
- The company gains an experienced biotech finance executive with M&A, operations and capital-markets expertise.
- Management states the transition is not related to accounting disagreements, reducing concern over financial reporting integrity.
- Severance and inducement equity create modest near-term cash outflow and long-term dilution, but no immediate impact on operating results.
A press release dated July 1, 2025 regarding these changes was furnished as Exhibit 99.1.